Hope for APOE4 Carriers (ALZ-801 Trial Results + Options Available Today)

ALZ-801 (valiltramiprosate) is an oral prodrug of homotaurine developed by Alzheon. Unlike antibody drugs that clear existing amyloid plaques, ALZ-801 prevents toxic beta-amyloid oligomers from forming in the first place. It changes the shape of amyloid proteins to block clustering into the small, synapse-damaging oligomers APOE4 carriers produce in higher quantities (approximately 3x more). It is dosed at 265 mg twice daily and achieves about 40% brain penetration.

In MCI APOE4 carriers, ALZ-801 showed a 52% benefit on ADAS-Cog (52% less cognitive decline than placebo), 102% benefit on CDR-SB (no decline on the functional endpoint), preservation of brain volume with decreased atrophy across all regions, and some super-responders showing actual brain volume increase over 78 weeks. Strong correlation between brain preservation and cognitive benefit suggests real neuroprotection rather than symptom management.

Yes, dramatically so. ALZ-801 showed zero ARIA-E (brain swelling) and zero ARIA-H (microbleeds) in trials. Most common side effect was mild nausea. Compare this to Leqembi, which causes ARIA-E in 20% of all patients and 40% of APOE4 carriers, some fatal, requiring frequent MRI monitoring. Many APOE4 carriers cannot safely take existing antibody treatments. ALZ-801 finally offers APOE4 carriers an amyloid-targeted option without the bleeding risk.

ALZ-801 is a valyl ester prodrug of homotaurine that dramatically improves absorption, maintains stable blood levels, and achieves therapeutic brain concentrations. The earlier homotaurine Alphase trial (2011) failed at 100-150 mg twice daily due to poor bioavailability, high GI side effects, and inadequate brain concentrations. ALZ-801 uses 265 mg twice daily with better pharmacokinetics. OTC homotaurine is available in Canada and Europe but may not replicate ALZ-801 effectiveness.

ALZ-801 is currently in Phase 3 trials with a confirmatory study planned before FDA submission. It is not yet approved. When available, it is projected to cost approximately 70% less than current antibody treatments (which run about $26,500+ annually) and will be taken as simple twice-daily pills at home, eliminating monthly IV infusions, infusion center visits, and caregiver burden. The oral format makes long-term treatment sustainable.

Dr. Kevin Tran August 04, 2025 Note: This post covers both the promising ALZ-801 clinical data and practical considerations for those exploring available options today - see the final section for details. I'm not affiliated with Alzheon and have no financial ties with Alzheon or Homotaurine of any kind. This post is based on the July 2025 AAIC session titled “Inhibition of Beta Amyloid Oligomer Neurotoxicity with Oral Valiltramiprosate.”